Related Experiment Video
Updated: Aug 17, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
[Syndrome of inappropriate ADH secretion (SIADH) in small-cell bronchus carcinoma]
A von Rohr1, T Cerny, R A Joss
1Institut für Medizinische Onkologie, Universität, Inselspital Bern.
Abstract:
Based upon the pertinent literature, the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients with small cell lung cancer is reviewed. Small cell lung cancer is a distinct tumor with neuroendocrine features capable of producing peptide hormones amongst which the antidiuretic hormone (ADH, arginine vasopressin) is one of the most frequent. Paraneoplastic SIADH may result from ectopic ADH production or from other tumor-related mechanisms leading to increased pituitary ADH secretion. The overt SIADH is characterized by neurological and psychiatric symptoms attributable to cerebral edema. Pooled published data suggest that the average incidence of clinically manifest SIADH in patients with newly diagnosed small cell lung cancer is 4%. Cases without clinical symptoms, detectable by laboratory tests only, are more frequent: hyponatremia, serum hypoosmolality and urine hyperosmolality are present in 14%, and an inappropriately elevated level of immunoreactive ADH in 38% of all patients respectively. Successful treatment of the underlying tumor, accompanied by a restricted fluid intake in severe cases, will usually result in prompt disappearance of the paraneoplastic SIADH. During and after the tumor treatment, plasma ADH may be useful as a tumor marker.
Insights
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) is common in small cell lung cancer patients, often presenting subtly. Early detection and tumor treatment are key to managing SIADH and may utilize antidiuretic hormone (ADH) as a tumor marker.
Area of Science:
- Endocrinology
- Oncology
- Nephrology
Context:
- Small cell lung cancer (SCLC) is a neuroendocrine tumor.
- SCLC can ectopically produce peptide hormones, including antidiuretic hormone (ADH).
- Paraneoplastic SIADH is a recognized complication of SCLC.
Purpose:
- To review the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion (SIADH) in small cell lung cancer (SCLC).
- To discuss the mechanisms, clinical presentation, incidence, and management of SIADH in SCLC patients.
Summary:
- Paraneoplastic SIADH in SCLC can result from ectopic ADH production or other tumor-related mechanisms.
- Clinically manifest SIADH occurs in approximately 4% of SCLC patients, with neurological symptoms due to cerebral edema.
- Subclinical SIADH (hyponatremia, hypoosmolality, urine hyperosmolality) is more frequent (14%), with elevated ADH levels in 38% of patients.
- Treatment involves addressing the underlying SCLC and fluid restriction; plasma ADH may serve as a tumor marker.
Impact:
- Highlights the significant incidence of SIADH in SCLC, both overt and subclinical.
- Emphasizes the role of ADH in SCLC pathogenesis and its potential as a tumor marker.
- Informs clinical practice regarding the diagnosis and management of SIADH in SCLC patients.
More Related Videos
07:43Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
10:21Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
Published on: September 20, 2024
Related Concept Videos
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Cushing Syndrome I: Introduction
Cushing Syndrome II: Pathophysiology
Asthma III: Clinical Manifestations
Chronic Obstructive Pulmonary Disease I: Introduction
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features